Has the mineralocorticoid receptor antagonist paradigm shifted in HFpEF and HFmREF? an era-based systematic review of finerenone versus steroidal mras

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

About the speaker

Doctor Rubiya Ali

Memorial Healthcare System, Pembroke Pines (United States of America)

6 More presentations in this session

Presentation thumbnail

Prognostic value of hyperkalemia and mineralocorticoid receptor antagonist use in heart failure: a national registry study

Doctor K. Berge (Nordbyhagen, NO)

Presentation thumbnail

Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort

Doctor A. Ambrosy (San Francisco, US)

Presentation thumbnail

Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)

Mr A. Hernandez Concepcion (Palmas de Gran Canaria, Las, ES)

Presentation thumbnail

SENEKA: a randomized clinical trial to optimize RAASi therapy using sodium zirconium cyclosilicate in elderly patients with heart failure and chronic kidney disease at risk of hyperkalemia

Doctor C. Bonanad Lozano (Valencia, ES)

Presentation thumbnail

Mineralocorticoid receptor antagonists in heart failure: real-world uptake, dose titration, hyperkalaemia trends, and potassium binder use

Doctor T. Furlan (Trbovlje, SI)

Access the full session

Session thumbnail

Mineralocorticoid receptor antagonists: from trials to real life

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Presentation

Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources